Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

BACKGROUND: We showed in a randomized double-blinded placebo-controlled clinical trial that octreotide long-acting repeatable depot.® (OctLAR(®)) for 12 months reduces kidney and liver growth in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver growth...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hogan, Marie C., Masyuk, Tetyana V., Page, Linda, Holmes, David R., Li, Xujian, Bergstralh, Eric J., Irazabal, Maria V., Kim, Bohyun, King, Bernard F., Glockner, James F., LaRusso, Nicholas F., Torres, Vicente E.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2012
Sujets:
Clinical Science
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3433774/
https://ncbi.nlm.nih.gov/pubmed/22773240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfs152
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires